Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs)
have revolutionized psychiatric care in terms of facilitating discharge from hospital and …

Background: Tardive dyskinesia (TD) is a movement disorder that causes involuntary,
repetitive body movements and is commonly seen in patients who are on long-term …

Phosphoinositides, the seven phosphorylated derivatives of phosphatidylinositol have
emerged as regulators of key sub-cellular processes such as membrane transport …

One of the great mysteries in dystonia pathophysiology is the role of environmental factors in
disease onset and development. Progress has been made in defining the genetic …

Tardive dyskinesia (TD) is a serious and potentially irreversible side effect of long-term
exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial …

GSK3B, BDNF, NGF, NRG1, HTR2C, and PIP4K2A play important roles in molecular
mechanisms of psychiatric disorders. GSK3B occupies a central position in these molecular …

Tardive dyskinesia (TD) is a hyperkinetic movement disorder caused by the use of
dopamine receptor-blocking agents (DRBAs), a category of medications that includes first …

We provide an overview of the recent achievements in psychiatric genetics research in the
Russian Federation and present genotype-phenotype, population, epigenetic, cytogenetic …

Tardive dyskinesia (TD) is a severe condition characterized by repetitive involuntary
movement of orofacial regions and extremities. Patients treated with antipsychotics typically …

Показана большая распространенность больных шизофренией, нуждающихся в
стационарном лечении, в том числе повторно, что является свидетельством тяжести …